jueves, 19 de noviembre de 2026
First drug for Lowe syndrome could soon reach clinical trials Patients could finally have a therapy available if the repurposed drug is successful. The trial protocol is under review with the Italian Medicines Agency. Written byAllison Whitten, PhD
First drug for Lowe syndrome could soon reach clinical trials
Patients could finally have a therapy available if the repurposed drug is successful. The trial protocol is under review with the Italian Medicines Agency.
Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/first-drug-for-lowe-syndrome-could-soon-reach-clinical-trials-17672
The ultimate goal in drug discovery is to identify the mechanistic cause of a disease, develop a therapeutic to target it, and then test the efficacy in humans with the condition. But it’s rarely that easy, and each step can take years or even decades.
Antonella De Matteis’ lab appears to be successfully following this path for Lowe syndrome, a rare X-linked disorder with mutations in the OCLR gene that causes issues with the eyes, brain, and kidneys. After 20 years of studying the mechanistic cause of the disease, her lab has now identified a novel biological cause behind the kidney disease aspect and demonstrated that a repurposed drug can target it in patient-derived cells, kidney organoids, and animal models. Their work was published recently in Signal Transduction and Targeted Therapy.
The findings will likely lead to the first drug in clinical trials for Lowe syndrome, if the Italian Medicines Agency accepts the Phase 2 submission from Can-Fite BioPharma.
”We now finally have a tangible opportunity to offer people living with Lowe syndrome and their families, who have supported our work throughout these years, a real prospect for the future,” Leopoldo Staiano, a molecular biologist at the Telethon Institute of Genetics and Medicine and the CNR Institute of Genetic and Biomedical Research, and the first author of the study, said in the press release.
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario